Key result
Guideline-directed medical therapy for chronic kidney disease and type 2 diabetes has low uptake, but multidisciplinary programs can improve care delivery and delay disease progression.
Why the study?
Although GDMT is a proven approach to manage CKD and type 2 diabetes, adherence is low and multifactorial, presenting opportunities to improve care delivery.
Answers are grounded in this paper and cite their sources.
Applying multidisciplinary team-based approaches from heart failure management could improve the low uptake of guideline-directed medical therapy in patients with CKD and type 2 diabetes.
Although guideline-directed medical therapy (GDMT) is an evidence-based, proven approach to manage chronic kidney disease and type 2 diabetes (CKD + T2DM), adherence is low and multifactorial. Opportunities exist to improve care delivery, thus delaying disease progression, avoiding unnecessary costs, and potentially improving quality of life for patients both diagnosed and yet to be diagnosed. • Guideline-directed medical therapy (GDMT) is designed to reduce morbidity and mortality associated with chronic diseases. • Uptake of GDMT in chronic kidney disease and type 2 diabetes (CKD+T2D) is low and multifactorial. • Successful GDMT programs create multidisciplinary teams that prioritize improvements in quality, patient safety, and workplaces. • Opportunities exist to improve care, delay disease progression, avoid extra costs, and improve quality of life for patients.
No takes yet. Share an insight, caveat, or question.
Rollins et al. (2025) conducted a review in Chronic kidney disease and type 2 diabetes (CKD + T2D). Guideline-directed medical therapy (GDMT) was evaluated. Guideline-directed medical therapy for chronic kidney disease and type 2 diabetes has low uptake, but multidisciplinary programs can improve care delivery and delay disease progression.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: